Prothena Corp. Plc (PRTA)
9.57
-0.12
(-1.19%)
USD |
NASDAQ |
Sep 03, 15:41
Prothena Research and Development Expense (Annual) : 134.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 134.85M |
| December 31, 2024 | 222.52M |
| December 31, 2023 | 220.57M |
| December 31, 2022 | 135.56M |
| December 31, 2021 | 82.28M |
| December 31, 2020 | 74.88M |
| December 31, 2019 | 50.84M |
| December 31, 2018 | 101.18M |
| Date | Value |
|---|---|
| December 31, 2017 | 134.55M |
| December 31, 2016 | 119.53M |
| December 31, 2015 | 58.44M |
| December 31, 2014 | 38.45M |
| December 31, 2013 | 26.05M |
| December 31, 2012 | 34.14M |
| December 31, 2011 | 24.20M |
| December 31, 2010 | 9.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Alkermes Plc | 318.36M |
| Amarin Corp. Plc | 16.82M |
| Agenus, Inc. | 79.34M |
| Amgen, Inc. | 6.974B |
| Anika Therapeutics, Inc. | 25.77M |